Eric Dohrenwend

About Eric Dohrenwend

Experienced clinical research professional with over 14 years in oncology clinical trials. Experiences includes over 7 years in immuno-oncology clinical trial management on Phase 1-3 studies, 5 years on-site monitoring as an oncology CRA and 2 years as a study coordinator. Therapeutic experience includes over 14 years in oncology, in Phases 1-3 studies. Oncology indications include Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Myelofibrosis, NSCLC, MBC, Head and Neck Squamous Cell Carcinoma, Gastric, Melanoma, Sarcoma, Prostate, and Pancreatic cancer.

Experience

1. Senior Clinical Study Manager

   BeOne Medicines

   Sep 2022 — Present · Ridgefield Park, NJ, US

   Led USA clinical operations team on Phase 1-2 NSCLC and HNSCC immune-oncology study from site identification through site Close-Out Visits, including multiple Safety Monitoring Committee (SMC) and Interim Analysis snapshots.• Led USA clinical operations team on Phase 3 MCL study from site identification through site selection.• Led USA-Canada clinical operations team on Phase 3 pivotal CLL study for site identification.• Represent North and South America region on portfolio-level initiative to implement novel strategies to minimize clinical database snapshot duration.• Review and approve monitoring visit reports and provide feedback.• Review and approval of pass-through invoices and subject visits payments from sites.• Review study level documents and provide feedback such on them such as protocols, informed consent forms, pharmacy manuals, monitoring plan, project management plans, deviation plans and study oversight plans.• Create and approve country and site level informed consent forms.• Host weekly regional meetings with internal regional team members, approve minutes and prepare agenda.• Attend global trial team meetings and contribute to agenda on a bi-weekly basis.• Serve on task force to revise company policies on study strategic feasibility, site identification, site selection and activation processes for all clinical trials globally.

Education

• Rutgers University

  Masters in Business and Science, Drug Discovery and Development

• Binghamton University

  BS, Psychobiology

  2006 — 2009